Bibliography
- Baganz H, May HJ. Vasoactivity, hypotensive agents. US3966757A; 1976
- Sjoerdsma A. Antihypertensive compositions of 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole and N-(2-chloroethyl)-N-(1-methyl-2-phenoxy-ethyl)benzenemethanamine. US4189492A; 1980
- White HC. 2-((2,6-substituted)phenoxymethyl)-2-imidazolines. US3449357A; 1969
- White HC. 2-((3,4-dihalophenoxy)methyl)-2-imidazoline. US3449355A; 1969
- Betzing H, Biedermann J. Chemistry of lofexidine. Arzneimittelforschung 1982;32:916-18
- Wagener HH, Genthe H. Characteristics of lofexidine in pharmacological screening. Arzneimittelforschung 1982;32:918-23
- Graf E. Actions of lofexidine on isolated heart and smooth muscle preparations. Arzneimittelforschung 1982;32:923-30
- Graf E, Doppelfeld IS, Prop G. Animal experiments on the cardiovascular effects of lofexidine. Arzneimittelforschung 1982;32:941-55
- Tsai TH, Beitman RE, Gibson JP, et al. Teratologic and reproductive studies of lofexidine. Arzneimittelforschung 1982;32:962-6
- Dollery CT, Reid JL. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. Arzneimittelforschung 1982;32:984-7
- Washton A, Resnick R, Perzel JR, et al. Lofexidine, a clonidine analogue effective in opiate withdrawal. Lancet 1981;317:991-3
- Jing Li, Liu C, Sun X. Lofexidine modulates expression of c-Fos mRNA in locus coeruleus of morphine dependent rats. Chin J Psychiatry 2000;33:164-6
- Li J, Liu C, Sun X, et al. Lofexidine modulates expression of Fos protein in locus coeruleus of morphine dependent rats. Chin J Drug Depend 2000;9(3):177-8
- Curran EJ, Akil H, Watson SJ. Psychomotor stimulant- and opiate-induced c-Fos mRNA expression patterns in the rat forebrain: comparisons between acute drug treatment and a drug challenge in sensitized animals. Neurochem Res 1996;21:1425-35
- Pb T, Je van K, Ym HZ. Binding of (+/−)-3H-lofexidine to alpha-adrenoceptors in membranes from rat brain. Arch Int Pharmacodyn Ther 1983;261:23-35
- Buccafusco JJ, Lapp CA, Westbrooks KL, et al. Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 1995;273:1162-71
- Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53:153-73
- Wilffert B, Mathy MJ, Batink HD, et al. Interference of enantiomers of lofexidine with alpha-adrenoceptors. Arch Int Pharmacodyn Thérapie 1985;273:18-32
- Biedermann J, León-Lomelí A, Borbe HO, et al. Two stereoisomeric imidazoline derivatives: synthesis and optical and alpha 2-adrenoceptor activities. J Med Chem 1986;29:1183-8
- Milligan G. Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci 2003;24:87-90
- Schroeder KS, Neagle BD. FLIPR: a new instrument for accurate, high throughput optical screening. J Biomol Screen 1996;1:75-80
- Williams C. cAMP detection methods in HTS: selecting the best from the rest. Nat Rev Drug Discov 2004;3:125-35
- Crooks PA, Vartak AP. Enantioselective synthesis of (+) and (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-3ene. US20100087657A1; 2010
- Vartak AP, Crooks PA. A scalable, enantioselective synthesis of the alpha2-adrenergic agonist, lofexidine. Org Process Res Dev 2009;13:415-19
- Al-Ghananeem AM. Sustained-release formulations comprising lofexidine for oral delivery. EP2363116A1; 2011
- Al-Ghananeem AM. Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery. US20110097393A1; 2011
- Digenis GA, Al-Ghananeem AM, Malkawi A. Selective release of non-racemic mixtures of two enantiomers from tablets and capsules. WO2010075275A1; 2010
- Bearn J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend 1996;43:87-91
- Kahn A, Mumford JP, Rogers GA, et al. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend 1997;44:57-61
- Lin SK, Strang J, Su LW, et al. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend 1997;48:127-33
- Yu E, Miotto K, Akerele E, et al. A phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008;97:158-68
- Strang J, Bearn J, Gossop M. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict Am Acad Psychiatr Alcohol Addict 1999;8:337-48
- Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01820442